Theranostics 2020; 10(6):2645-2658. doi:10.7150/thno.38533 This issue Cite

Research Paper

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

Levin Schriewer1,2*, Kerstin Schütze1,2*, Katharina Petry1,2*, Julia Hambach1,2, William Fumey1,2, Julia Koenigsdorf1,2, Natalie Baum1,2, Stephan Menzel2, Björn Rissiek3, Kristoffer Riecken4,6, Boris Fehse4,6, Jana Larissa Röckendorf1,2, Joanna Schmid1,2, Birte Albrecht1,2, Hans Pinnschmidt5, Francis Ayuk6, Nicolaus Kröger6, Mascha Binder7,8, Gunter Schuch9, Timon Hansen9, Friedrich Haag2, Gerhard Adam1, Friedrich Koch-Nolte2#, Peter Bannas1#✉

1. Department of Diagnostic and Interventional Radiology and Nuclear medicine, University Medical Center, Hamburg-Eppendorf, Germany.
2. Institute of Immunology, University Medical Center, Hamburg-Eppendorf, Germany.
3. Department of Neurology, University Medical Center, Hamburg-Eppendorf, Germany.
4. Research Department Cell and Gene Therapy, University Medical Center, Hamburg-Eppendorf, Germany.
5. Institute of Medical Biometry and Epidemiology, University Medical Center, Hamburg-Eppendorf, Germany.
6. Department of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Germany.
7. Department of Oncology and Hematology, University Medical Center, Hamburg-Eppendorf, Germany.
8. Department of Haematology and Oncology, University Hospital Halle, Halle, Germany.
9. Hematology and Oncology Center Altona (HOPA), Hamburg, Germany.
Nanobody® is a trademark of Ablynx. In this paper we use nanobody as the generic term for the recombinant VHH domain of a llama heavy chain antibody.
* LS, KS, and KP contributed equally
# FK-N and PB share senior authorship

Citation:
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf JL, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics 2020; 10(6):2645-2658. doi:10.7150/thno.38533. https://www.thno.org/v10p2645.htm
Other styles

File import instruction

Abstract

Graphic abstract

Rationale: CD38 is a target for the therapy of multiple myeloma (MM) with monoclonal antibodies such as daratumumab and isatuximab. Since MM patients exhibit a high rate of relapse, the development of new biologics targeting alternative CD38 epitopes is desirable. The discovery of single-domain antibodies (nanobodies) has opened the way for a new generation of antitumor therapeutics. We report the generation of nanobody-based humanized IgG1 heavy chain antibodies (hcAbs) with a high specificity and affinity that recognize three different and non-overlapping epitopes of CD38 and compare their cytotoxicity against CD38-expressing hematological cancer cells in vitro, ex vivo and in vivo.

Methods: We generated three humanized hcAbs (WF211-hcAb, MU1067-hcAb, JK36-hcAb) that recognize three different non-overlapping epitopes (E1, E2, E3) of CD38 by fusion of llama-derived nanobodies to the hinge- and Fc-domains of human IgG1. WF211-hcAb shares the binding epitope E1 with daratumumab. We compared the capacity of these CD38-specific hcAbs and daratumumab to induce CDC and ADCC in CD38-expressing tumor cell lines in vitro and in patient MM cells ex vivo as well as effects on xenograft tumor growth and survival in vivo.

Results: CD38-specific heavy chain antibodies (WF211-hcAb, MU1067-hcAb, JK36-hcAb) potently induced antibody-dependent cellular cytotoxicity (ADCC) in CD38-expressing tumor cell lines and in primary patient MM cells, but only little if any complement-dependent cytotoxicity (CDC). In vivo, CD38-specific heavy chain antibodies significantly reduced the growth of systemic lymphomas and prolonged survival of tumor bearing SCID mice.

Conclusions: CD38-specific nanobody-based humanized IgG1 heavy chain antibodies mediate cytotoxicity against CD38-expressing hematological cancer cells in vitro, ex vivo and in vivo. These promising results of our study indicate that CD38-specific hcAbs warrant further clinical development as therapeutics for multiple myeloma and other hematological malignancies.


Citation styles

APA
Schriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., Fehse, B., Röckendorf, J.L., Schmid, J., Albrecht, B., Pinnschmidt, H., Ayuk, F., Kröger, N., Binder, M., Schuch, G., Hansen, T., Haag, F., Adam, G., Koch-Nolte, F., Bannas, P. (2020). Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics, 10(6), 2645-2658. https://doi.org/10.7150/thno.38533.

ACS
Schriewer, L.; Schütze, K.; Petry, K.; Hambach, J.; Fumey, W.; Koenigsdorf, J.; Baum, N.; Menzel, S.; Rissiek, B.; Riecken, K.; Fehse, B.; Röckendorf, J.L.; Schmid, J.; Albrecht, B.; Pinnschmidt, H.; Ayuk, F.; Kröger, N.; Binder, M.; Schuch, G.; Hansen, T.; Haag, F.; Adam, G.; Koch-Nolte, F.; Bannas, P. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics 2020, 10 (6), 2645-2658. DOI: 10.7150/thno.38533.

NLM
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf JL, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics 2020; 10(6):2645-2658. doi:10.7150/thno.38533. https://www.thno.org/v10p2645.htm

CSE
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf JL, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P. 2020. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics. 10(6):2645-2658.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image